Cargando…

Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men

Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of preclinical mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Hoek, Anita M., Verschuren, Lars, Caspers, Martien P. M., Worms, Nicole, Menke, Aswin L., Princen, Hans M. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930243/ https://www.ncbi.nlm.nih.gov/pubmed/33658534 http://dx.doi.org/10.1038/s41598-021-83974-8

Ejemplares similares

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
por: Inia, José A., et al.
Publicado: (2023)

Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice
por: Tsai, Hung-Cheng, et al.
Publicado: (2019)

A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology
por: van den Hoek, Anita M., et al.
Publicado: (2020)

Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice
por: Pouwer, Marianne G, et al.
Publicado: (2019)

Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis
por: van den Hoek, Anita M., et al.
Publicado: (2022)

Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation
por: Inia, José A., et al.
Publicado: (2023)

Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice
por: Morrison, Martine C., et al.
Publicado: (2018)

Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice
por: van den Hoek, Anita M., et al.
Publicado: (2019)

Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH
por: Perakakis, Nikolaos, et al.
Publicado: (2021)

Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
por: Schuster, Susanne, et al.
Publicado: (2019)

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
por: van Koppen, Arianne, et al.
Publicado: (2017)

Mild Exercise Does Not Prevent Atherosclerosis in APOE*3‐Leiden.CETP Mice or Improve Lipoprotein Profile of Men with Obesity
por: In het Panhuis, Wietse, et al.
Publicado: (2020)

Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor
por: Kamata, Shotaro, et al.
Publicado: (2023)

Caloric Restriction Combined with Immobilization as Translational Model for Sarcopenia Expressing Key-Pathways of Human Pathology
por: de Jong, Jelle C.B.C, et al.
Publicado: (2023)

Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice
por: Hu, Chunxiu, et al.
Publicado: (2011)

Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice
por: Auvinen, Hanna E., et al.
Publicado: (2013)

Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
por: Kühnast, Susan, et al.
Publicado: (2013)

Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-β Signaling Pathways in Human Hepatic Stellate Cells
por: Gart, Eveline, et al.
Publicado: (2021)

Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice
por: van Keulen, Danielle, et al.
Publicado: (2018)

Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr−/−.Leiden mice
por: Gart, Eveline, et al.
Publicado: (2023)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
por: Roth, Jonathan D., et al.
Publicado: (2019)

Xanthohumol Prevents Atherosclerosis by Reducing Arterial Cholesterol Content via CETP and Apolipoprotein E in CETP-Transgenic Mice
por: Hirata, Hiroshi, et al.
Publicado: (2012)

Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor
por: Boeckmans, Joost, et al.
Publicado: (2019)

Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans
por: van Keulen, Danielle, et al.
Publicado: (2019)

Lipidomics Reveals Multiple Pathway Effects of a Multi-Components Preparation on Lipid Biochemistry in ApoE*3Leiden.CETP Mice
por: Wei, Heng, et al.
Publicado: (2012)

Continuous Light Does Not Affect Atherosclerosis in APOE*3-Leiden.CETP Mice
por: Schilperoort, Maaike, et al.
Publicado: (2020)

Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice
por: Seidel, Florine, et al.
Publicado: (2022)

CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet
por: Zhu, Lin, et al.
Publicado: (2018)

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
por: Landlinger, Christine, et al.
Publicado: (2017)

Cholesteryl Ester Transfer Protein (CETP) expression does not affect glucose homeostasis and insulin secretion: studies in human CETP transgenic mice
por: Raposo, Helena F., et al.
Publicado: (2016)

CETP Expression Protects Female Mice from Obesity-Induced Decline in Exercise Capacity
por: Cappel, David A., et al.
Publicado: (2015)

Key Inflammatory Processes in Human NASH Are Reflected in Ldlr(−/−).Leiden Mice: A Translational Gene Profiling Study
por: Morrison, Martine C., et al.
Publicado: (2018)

Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors
por: Mabuchi, Hiroshi, et al.
Publicado: (2014)

Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice
por: Jongejan, Yvonne K., et al.
Publicado: (2021)

Mechanism-Based Biomarker Prediction for Low-Grade Inflammation in Liver and Adipose Tissue
por: van Bilsen, Jolanda H. M., et al.
Publicado: (2021)

CETP Expression in Bone-Marrow-Derived Cells Reduces the Inflammatory Features of Atherosclerosis in Hypercholesterolemic Mice
por: Rentz, Thiago, et al.
Publicado: (2023)

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
por: Koop, Anja Christina, et al.
Publicado: (2020)

A 3‐week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death
por: Briand, François, et al.
Publicado: (2020)

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice
por: Pouwer, Marianne G., et al.
Publicado: (2020)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c4rojvph3brkoialu0p0f841im